ALERGOPREVENT 2 ml. 10 ampoules

Composition of the medicinal product:
1 ml solution contains:
Human normal immunoglobulin - 6 mg
Histamine dihydrochloride - 0,075 μg
Sodium chloride - 9 mg
Water for injection - up to 1 ml

Pharmaceutical form:
A solution for injection.
Ampoules of 2 ml for subcutaneous administration.

Pharmacological Action:
Alergoprevent represents antigen complex consisting of carrier normal human immunoglobulin and hapten - histamine. This complex injected into the body stimulates active defenses against histamine in the blood of patients suffering o allergic diseases.

Therapeutic indications:
Used for the treatment of allergic diseases - urticaria, allergic rhinitis in children with polialergiya edema edema, neurodermatitis, atopic dermatitis, migraine.

Contraindications:
Intolerance to homologous immunoglobulins, hypersensitivity to any components of the product. In intolerance assess the risk / benefit.

Special precautions:
This preparation should not be injected intravenously risk / shock / intramuscularly.

In case of shock, treatment should follow the instructions for the shock contemporary therapy.

Outstanding allergic reactions to Alergoprevent administered subcutaneously are rare. Immunoglobulins intolerance may develop in very rare cases of IgA deficiency in patients with anti-IgA antibodies.
Suspicion of allergic or anaphylactic type require immediate discontinuation of the injection.
Not recommended drug administration during menstruation / may enhance bleeding / temperature conditions, acute attacks of asthma or eczema.
Patients should be observed for at least 20 minutes after injection.


Use in pregnancy and lactation:
Not recommended drug administration during pregnancy.

Effects on ability to drive and use machines:
If injection of the drug is associated with feelings of dizziness for several hours should avoid driving or operating machinery.

Data excipients
Alergoprevent contains the following inactive ingredients:
9 g / I NaCl - stabilizer
Water for injections
There is no evidence that the excipients included in the composition of Alergoprevent can affect the safety and effectiveness of the product.

Information on proper use:
Alergoprevent injected subcutaneously, while respecting the rules of asepsis in the upper third of the outside shoulder. Injection is carried out very slowly for about 1.5 to 2 minutes.

The dose of Alergoprevent depends on age. A single dose is:
- For children up to 3 years - 0.5 ml
- For children over 3 years - 1 ml
- For adults - 2 ml

In clinical practice, the following dosage regimens depending on clinical condition and age of the patient:
For children:
Children up to 5 years:
First week first application 0.25 ml
First week 2 First application 0.5 ml
Second week first application 0.75 ml
Second week 2 First application 1.0 ml

Continued twice in 7 days in 1 ml, then twice in 14 days in 1 ml, then twice in 21 days in 1 ml.

At the discretion of the physician treatment can continue with dosages of 1 ml after 21 days to a total Alergoprevent 10 ml.

Children 5 to 10 years:
First application first week of 0.5 ml
Second application first week of 0.75 ml
First application 2 Week-1.0 ml
Second application 2 Week-1.25 ml
Further treatment continues under the scheme as dosage is 1.25 ml per application.

Children from 10 to 14 years:
First week first application 0.5 ml
First week 2 First application 0.75 ml
Second week first application 1.0 ml
Second week 2 First application 1.5 ml

Further treatment continues under the scheme as dosage is 1.5 ml per application.

For adults:
First week first application 0.5 ml
First week 2 First application 1.0 ml
Second week first application 1.5 ml
Second week 2 First application 2ml
Further treatment continues under the scheme as dosage is 2 ml per application.

Alergoprevent should not be mixed with other medicinal products.

Undesirable effects:
After the first injection sometimes appears dizziness, mild hyperemia of the puncture site, and perhaps slightly exacerbation of clinical symptoms, but it should not be a refusal of treatment.
When medicinal products prepared from human blood or plasma can not be ruled out entirely transmission of transmissible infections.
This also applies to pathogens of unknown until now nature.

To reduce the risk of transmission of infectious agents to the donors of blood or plasma are selected according to strict criteria, donated blood or plasma be tested for the absence of HBsAg, anti-HCV antibodies, antibodies and syphilis plasma pools were tested for HBsAg, anti-HCV antibodies and anti HIV 1,2 antibodies and the manufacturing process includes procedures leading to the elimination / inactivation of adventitious viral agents.